company background image
ALNOV logo

Novacyt ENXTPA:ALNOV Stock Report

Last Price

€0.67

Market Cap

€46.9m

7D

-3.1%

1Y

9.4%

Updated

20 Jan, 2025

Data

Company Financials

Novacyt S.A.

ENXTPA:ALNOV Stock Report

Market Cap: €46.9m

ALNOV Stock Overview

Provides in vitro and molecular diagnostic tests for a range of infectious diseases in the United Kingdom, rest of Europe, France, the United States, the Asia Pacific, the Middle East, and Africa. More details

ALNOV fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Risk Analysis

Highly volatile share price over the past 3 months compared to the French market

Earnings have declined by 48.1% per year over past 5 years

Does not have a meaningful market cap (€47M)


My Notes

Capture your thoughts, links and company narrative

Novacyt S.A. Competitors

GenSight Biologics

ENXTPA:SIGHT

€35.2m

Poxel

ENXTPA:POXEL

€11.4m

Transgene

ENXTPA:TNG

€94.4m

Adocia

ENXTPA:ADOC

€97.7m

Price History & Performance

Summary of share price highs, lows and changes for Novacyt
Historical stock prices
Current Share Price€0.67
52 Week High€1.59
52 Week Low€0.49
Beta-1.82
1 Month Change8.31%
3 Month Change-4.73%
1 Year Change9.38%
3 Year Change-76.91%
5 Year Change225.98%
Change since IPO-92.36%

Recent News & Updates

There's No Escaping Novacyt S.A.'s (EPA:ALNOV) Muted Revenues

Jan 09
There's No Escaping Novacyt S.A.'s (EPA:ALNOV) Muted Revenues

Novacyt S.A. (EPA:ALNOV) Not Doing Enough For Some Investors As Its Shares Slump 36%

Sep 30
Novacyt S.A. (EPA:ALNOV) Not Doing Enough For Some Investors As Its Shares Slump 36%

Recent updates

There's No Escaping Novacyt S.A.'s (EPA:ALNOV) Muted Revenues

Jan 09
There's No Escaping Novacyt S.A.'s (EPA:ALNOV) Muted Revenues

Novacyt S.A. (EPA:ALNOV) Not Doing Enough For Some Investors As Its Shares Slump 36%

Sep 30
Novacyt S.A. (EPA:ALNOV) Not Doing Enough For Some Investors As Its Shares Slump 36%

Novacyt S.A. (EPA:ALNOV) Stock Catapults 39% Though Its Price And Business Still Lag The Industry

Aug 16
Novacyt S.A. (EPA:ALNOV) Stock Catapults 39% Though Its Price And Business Still Lag The Industry

Here's Why Novacyt (EPA:ALNOV) Must Use Its Cash Wisely

Aug 15
Here's Why Novacyt (EPA:ALNOV) Must Use Its Cash Wisely

Revenues Working Against Novacyt S.A.'s (EPA:ALNOV) Share Price

Jun 14
Revenues Working Against Novacyt S.A.'s (EPA:ALNOV) Share Price

Is Novacyt (EPA:ALNOV) In A Good Position To Deliver On Growth Plans?

Nov 28
Is Novacyt (EPA:ALNOV) In A Good Position To Deliver On Growth Plans?

We're Keeping An Eye On Novacyt's (EPA:ALNOV) Cash Burn Rate

Jul 04
We're Keeping An Eye On Novacyt's (EPA:ALNOV) Cash Burn Rate

Estimating The Fair Value Of Novacyt S.A. (EPA:ALNOV)

Jan 24
Estimating The Fair Value Of Novacyt S.A. (EPA:ALNOV)

With EPS Growth And More, Novacyt (EPA:ALNOV) Is Interesting

Mar 18
With EPS Growth And More, Novacyt (EPA:ALNOV) Is Interesting

With EPS Growth And More, Novacyt (EPA:ALNOV) Is Interesting

Nov 25
With EPS Growth And More, Novacyt (EPA:ALNOV) Is Interesting

Little Excitement Around Novacyt S.A.'s (EPA:ALNOV) Earnings As Shares Take 25% Pounding

Sep 29
Little Excitement Around Novacyt S.A.'s (EPA:ALNOV) Earnings As Shares Take 25% Pounding

Novacyt's (EPA:ALNOV) Wonderful 999% Share Price Increase Shows How Capitalism Can Build Wealth

Mar 08
Novacyt's (EPA:ALNOV) Wonderful 999% Share Price Increase Shows How Capitalism Can Build Wealth

Is Novacyt S.A.'s(EPA:ALNOV) Recent Stock Performance Tethered To Its Strong Fundamentals?

Jan 22
Is Novacyt S.A.'s(EPA:ALNOV) Recent Stock Performance Tethered To Its Strong Fundamentals?

Calculating The Intrinsic Value Of Novacyt S.A. (EPA:ALNOV)

Dec 15
Calculating The Intrinsic Value Of Novacyt S.A. (EPA:ALNOV)

We're Not Counting On Novacyt (EPA:ALNOV) To Sustain Its Statutory Profitability

Nov 19
We're Not Counting On Novacyt (EPA:ALNOV) To Sustain Its Statutory Profitability

Shareholder Returns

ALNOVFR BiotechsFR Market
7D-3.1%-3.0%4.1%
1Y9.4%-27.9%3.7%

Return vs Industry: ALNOV exceeded the French Biotechs industry which returned -27.1% over the past year.

Return vs Market: ALNOV exceeded the French Market which returned 4.3% over the past year.

Price Volatility

Is ALNOV's price volatile compared to industry and market?
ALNOV volatility
ALNOV Average Weekly Movement10.6%
Biotechs Industry Average Movement7.2%
Market Average Movement4.5%
10% most volatile stocks in FR Market9.3%
10% least volatile stocks in FR Market2.4%

Stable Share Price: ALNOV's share price has been volatile over the past 3 months compared to the French market.

Volatility Over Time: ALNOV's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of French stocks.

About the Company

FoundedEmployeesCEOWebsite
2006240Lyn Reeswww.novacyt.com

Novacyt S.A., together with its subsidiaries, provides in vitro and molecular diagnostic tests for a range of infectious diseases in the United Kingdom, rest of Europe, France, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, and Yourgene Health segments. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases.

Novacyt S.A. Fundamentals Summary

How do Novacyt's earnings and revenue compare to its market cap?
ALNOV fundamental statistics
Market cap€46.92m
Earnings (TTM)-€44.25m
Revenue (TTM)€21.98m

2.1x

P/S Ratio

-1.1x

P/E Ratio

Is ALNOV overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ALNOV income statement (TTM)
RevenueUK£18.56m
Cost of RevenueUK£29.52m
Gross Profit-UK£10.96m
Other ExpensesUK£26.40m
Earnings-UK£37.36m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.53
Gross Margin-59.05%
Net Profit Margin-201.27%
Debt/Equity Ratio0%

How did ALNOV perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/20 08:27
End of Day Share Price 2025/01/17 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Novacyt S.A. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mathieu JasminArkeon Finance
Johann CarrierInvest Securities
Stefan HamillNumis Securities Ltd.